Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinarest AF
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest AF is an oral fixed-dose combination therapy developed by Centaur Pharmaceuticals for the symptomatic relief of the common cold and allergic rhinitis, particularly in pediatric patients. The formulation is specifically designed to be antipyretic-free (containing no paracetamol/acetaminophen), which prevents accidental double-dosing of pain and fever reducers when multiple medications are co-administered. It contains two active pharmaceutical ingredients: chlorpheniramine maleate, a first-generation alkylamine antihistamine that acts as a competitive antagonist at the histamine H1 receptor to alleviate allergy symptoms such as sneezing, runny nose, and watery eyes; and phenylephrine hydrochloride, a selective alpha-1 adrenergic receptor agonist that acts as a vasoconstrictor to reduce swelling and congestion in the nasal passages. Sinarest AF is widely marketed in India in various pediatric-friendly oral formulations, including drops and syrups.
- Brand names
- Sinarest AFSinarest AF DropsSinarest AF Junior SyrupSinarest AF New SyrupSinarest AF SyrupSinarest AF Tablet
- Other names
- chlorphenamine + phenylephrinechlorphenamine maleate + phenylephrine hydrochloridechlorpheniramine + phenylephrinechlorpheniramine maleate + phenylephrine hydrochloride
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Sinarest AF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinarest AF.